Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

PhRMA Report: 465 Medicines in Development for Chronic Diseases Affecting Seniors

Washington, DC, March 21, 2013 — America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released yesterday by the Pharmaceutical Research and Manufacturers of America (PhRMA).

 With the population of Americans over 65 on the rise and life expectancy climbing, chronic diseases remain a principal threat to the health and productivity of older Americans, as well as to rising health care costs.  Innovative medicines have led to major advances against many chronic diseases ― and the robust discovery pipeline of new medicines portends continued progress for seniors and our health care system.

 These medicines ― all in clinical trials or under review by the Food and Drug Administration (FDA) ― are diverse in scope.  They include:

  • 142 for diabetes, which affects 10.9 million Americans age 65 and older.
  • 92 for rheumatoid arthritis and osteoarthritis, which affect 1.3 million Americans and 12.4 million people over age 65, respectively.
  • 82 for Alzheimer’s disease, which could afflict nearly 8 million people in the U.S. by 2030 unless a treatment or preventative measure is found.
  • 48 for heart failure (affecting 5.8 million Americans) and ischemic heart disease.
  • 40 for chronic obstructive pulmonary disease, which impacts more than 13 million adults, with the highest prevalence rate in those over age 65.

To access PhRMA’s press release, click here.